Quadrant Capital »

Enliven Therapeutics shares owned by Quadrant Capital

Quarter-by-quarter ownership of Enliven Therapeutics (ELVN) shares owned by Quadrant Capital from 13F filings

Historical chart of Quadrant Capital investment in Enliven Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Enliven Therapeutics held by Quadrant Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Enliven Therapeutics by Quadrant Capital

Quarter filed Position value Share count Share price at filing
2025-09-30 $6.0k 295 20.47

More positions owned by Quadrant Capital

Ishares Tr Core S&p500 Etf (IVV)
NVIDIA Corporation (NVDA)
Apple (AAPL)
Microsoft Corporation (MSFT)
Schwab Strategic Tr Fundamental Us L (FNDX)
J P Morgan Exchange Traded F Ultra Shrt Etf (JPST)
Alphabet Cap Stk Cl A (GOOGL)
Ishares Tr Core Msci Eafe (IEFA)
Amazon (AMZN)
Ishares Tr Core S&p Mcp Etf (IJH)
Broadcom (AVGO)
Meta Platforms Cl A (META)
Tesla Motors (TSLA)
Procter & Gamble Company (PG)
Taiwan Semiconductor Mfg Sponsored Ads (TSM)

View all positions for Quadrant Capital

Top funds holding Enliven Therapeutics

OrbiMed Advisors
FMR
Commodore Capital
Fairmount Funds Management
BlackRock
VR Adviser
Polar Capital Holdings
Vanguard Group
Henderson Group
Novo A/S
Pictet Asset Management Holding SA
Blackstone Group
Capital Research Global Investors
Citadel Advisors
Vestal Point Capital

View all funds holding Enliven Therapeutics